On Friday, Bank of America Merrill Lynch analyst Rachel McMinn increased the price objective for Gilead Sciences Inc. GILD from $96 to $107.
McMinn expects an increase in share price, "as investors gain visibility on HCV pricing in late 2013, obtain Phase 3 data in early 2014, observe the first wave of GILD's HCV launch in 2014, and get increased confidence in HIV sales durability." The analyst looked at key US< EU, and Japan HCV assumptions. Bank of America's peak US sales estimate is $6.5 billion in 20116 and $1.5 billion in 2017 in Europe. For ROW, McMinn assumes peak sales of $1.9 billion in 2023 and noted no sales prior to 2017.
Gilead Sciences closed at $71.63 on Thursday and is currently trading +3.70%. Gilead hit a new high earlier this morning at $75.21.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in